Abstract
The current review discusses microtubules and tau in the healthy brain and move on to the underling pathology of Alzheimers disease (AD) with emphasis on tau and neurofibrillary tangles. Tangles have been associated with cognitive dysfunction causing neurodegeneration in the absence of plaques. AD, the most abundant tauopathy is characterized by β-amyloid plaques and tau tangles. An abundance of tau inclusions, in the absence of β-amyloid deposits, defines Picks disease (frontotemporal lobar degeneration), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and other diseases. Our own focused research is on activity-dependent neuroprtective protein (ADNP). Our findings show that ADNP-deficiency leads to tauopathy which is inhibited by the ADNP derived drug candidate, davunetide (originally known as NAP). The current review further describes tau as a potential diagnostic marker followed by drug candidates that are aimed at fighting tau pathology. A recent historical perspective is the final comment of the manuscript. This paper is not a comprehensive review of the literature rather it gives my own point of view in the face of many publications and a great unmet need for future therapeutics. It is hoped that davunetide, a most advanced drug in clinical development will rapidly advance as a first effective treatment for a number of brain disorders broadly categorized as frontotemporal dementia (FTD) and serve as a prototype for future therapeutic development toward modification and remedy of currently intractable neurodegenerative diseases.
Keywords: Tau, Activity-dependent neuroprotective protein (ADNP), Davunetide (NAP).
Current Alzheimer Research
Title: Tau Pathology and Future Therapeutics
Volume: 7 Issue: 8
Author(s): I. Gozes
Affiliation:
Keywords: Tau, Activity-dependent neuroprotective protein (ADNP), Davunetide (NAP).
Abstract: The current review discusses microtubules and tau in the healthy brain and move on to the underling pathology of Alzheimers disease (AD) with emphasis on tau and neurofibrillary tangles. Tangles have been associated with cognitive dysfunction causing neurodegeneration in the absence of plaques. AD, the most abundant tauopathy is characterized by β-amyloid plaques and tau tangles. An abundance of tau inclusions, in the absence of β-amyloid deposits, defines Picks disease (frontotemporal lobar degeneration), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and other diseases. Our own focused research is on activity-dependent neuroprtective protein (ADNP). Our findings show that ADNP-deficiency leads to tauopathy which is inhibited by the ADNP derived drug candidate, davunetide (originally known as NAP). The current review further describes tau as a potential diagnostic marker followed by drug candidates that are aimed at fighting tau pathology. A recent historical perspective is the final comment of the manuscript. This paper is not a comprehensive review of the literature rather it gives my own point of view in the face of many publications and a great unmet need for future therapeutics. It is hoped that davunetide, a most advanced drug in clinical development will rapidly advance as a first effective treatment for a number of brain disorders broadly categorized as frontotemporal dementia (FTD) and serve as a prototype for future therapeutic development toward modification and remedy of currently intractable neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Gozes I., Tau Pathology and Future Therapeutics, Current Alzheimer Research 2010; 7 (8) . https://dx.doi.org/10.2174/156720510793611628
DOI https://dx.doi.org/10.2174/156720510793611628 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer,s Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Current Alzheimer Research subject Index To Volume 1
Current Drug Targets - CNS & Neurological Disorders Screening for Rare Genetic Variants Associated with Atherosclerosis: Opportunity for Personalized Medicine
Current Vascular Pharmacology Red Wine Consumption and Prevention of Atherosclerosis: An In Vitro Model Using Human Peripheral Blood Mononuclear Cells
Current Pharmaceutical Design The Effect of <i>Stachy sieboldii</i> MIQ. Supplementation on Modulating Gut Microflora and Cytokine Expression in Mice
Combinatorial Chemistry & High Throughput Screening Long Term Caregiving: Helping Families of Persons with Mild Cognitive Impairment Cope
Current Alzheimer Research Gene Therapy as a Novel Pharmaceutical Intervention for Stroke
Current Pharmaceutical Design AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer’s Disease
Current Neuropharmacology Physiologic Tailoring of Treatment in Resistant Hypertension
Current Cardiology Reviews Insights from Mouse Models to Understand Neurodegeneration in Down Syndrome
CNS & Neurological Disorders - Drug Targets A Role for Calcineurin in Alzheimers Disease
Current Neuropharmacology Diabetes Care: Risk Factors, Prediction, Prevention, and Individualized Treatment
Infectious Disorders - Drug Targets Synaptic Elimination in Neurological Disorders
Current Neuropharmacology Increased Alzheimer’s Disease Neuropathology is Associated with Type 2 Diabetes and ApoE ε4 Carrier Status
Current Alzheimer Research CoMFA, CoMSIA and HQSAR Studies of Acetylcholinesterase Inhibitors
Current Computer-Aided Drug Design Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment
Current Pharmaceutical Design Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies Tubulin-Independent Tau in Alzheimer’s Disease and Cancer: Implications for Disease Pathogenesis and Treatment
Current Alzheimer Research Study of Nutraceuticals and Phytochemicals for the Management of Alzheimer's Disease: A Review
Current Neuropharmacology Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation